CDT Equity restates Q1, rebrands, sees cash boost but widening loss, going‑concern risk

CDT Equity Inc. (NASDAQ: CDTTW)

What's happening inside the company
- The company completed a restatement of its Q1 2025 financials: an acquired diagnostic asset (Sarborg deliverable) was reclassified from R&D to a capitalized intangible, producing a $393 (in thousands) adjustment in Q1 2025.
- Corporate name change effective August 5, 2025 (Conduit Pharmaceuticals, Inc. → CDT Equity Inc.).
- Governance & leadership moves: 1‑for‑100 reverse stock split effective Jan 24, 2025; CEO transition - Dr. David Tapolczay resigned April 12, 2025 and Dr. Andrew Regan appointed CEO April 15, 2025.
- Heavy related‑party activity: Sarborg (related party) agreements include upfront cash and share payments and material prepayments; Nirland and A.G.P. related convertible notes and warrants remain significant items.

Key numbers & statistics (as restated)
- Total assets: $7,714 (in thousands) at March 31, 2025 (vs $4,193 at Dec 31, 2024).
- Cash and cash equivalents: $2,130 (in thousands) at March 31, 2025 (vs $554 at Dec 31, 2024).
- Total liabilities: $4,634 (in thousands) at March 31, 2025.
- Stockholders' equity (deficit): $3,080 (in thousands) at March 31, 2025 (improved from $(6,793) at Dec 31, 2024).
- Net loss (three months ended Mar 31): $(4,753) (in thousands) in 2025 vs $(3,552) in 2024.
- Operating loss: $(3,616) (in thousands) in Q1 2025.
- Research & development expense: $916 (in thousands) in Q1 2025 vs $128 in Q1 2024 (increase of $788; +616%).
- General & administrative expense: $2,700 (in thousands) in Q1 2025 vs $2,827 in Q1 2024.
- Other (expense) income, net: $(1,137) (in thousands) for Q1 2025 (includes large fair‑value movements on convertible notes and warrants).
- Convertible notes payable (fair value, Level 3): $2,663 (in thousands) at Mar 31, 2025 (down from $5,856 at Dec 31, 2024).
- Warrant liability: $8 (in thousands) at Mar 31, 2025 (down from $138 at Dec 31, 2024).
- Accumulated deficit: $(33,854) (in thousands) at Mar 31, 2025.
- Weighted‑average shares outstanding (basic & diluted): 3,885,758 for Q1 2025 (vs 738,295 in Q1 2024).
- Basic & diluted net loss per share: $(1.22) for Q1 2025 vs $(4.81) for Q1 2024.
- Shares issued / outstanding reported May 14, 2025: 11,961,460 shares.

Income statement - positives
- R&D spend increased meaningfully, indicating active development (R&D $916 → supports pipeline work and Sarborg/Charles River activity).
- G&A was slightly lower year-over-year (2,700 vs 2,827), showing modest cost control despite public‑company and transaction-related costs.
- Non‑cash adjustments and financing actions improved liquidity: proceeds from ATM program net $8,061 (in thousands) in Q1 2025 increased cash to $2,130 (in thousands).
- Restatement recognized a capitalized diagnostic asset ($400 purchase, $393 adjustment), moving part of prior R&D expense to an amortizable asset - reduces immediate expense and matches cost to future benefit.

Income statement - negatives
- Net loss widened to $(4,753) (in thousands).
- Large non‑operating volatility: a $1.8M loss on change in fair value of convertible notes contributed to other expense, producing a significant net other expense swing.
- High burn: cash used in operating activities was $(3,929) (in thousands) for the quarter - runway is a material concern absent additional financing.
- Accumulated deficit remains large: $(33,854) (in thousands).
- Earnings per share benefit is driven by a much larger share base (dilution), not improved core profitability - be cautious interpreting the improved per‑share metric.
- Heavy use of share issuance and convertible instruments increases dilution and fair‑value accounting volatility (warrants and convertible notes subject to Level 3 fair‑value remeasurements).

Risks and watch items (short checklist)
- Going concern: management states "substantial doubt" about ability to continue for 12 months without additional funding.
- A.G.P. Convertible Note: approximately $5.5M outstanding as of Mar 31, 2025 (subject to subsequent partial conversions; filing notes ~$4.2M remaining after conversions through Apr 16, 2025).
- Related‑party exposures: Sarborg (prepayments and shares issued), Nirland amendments/conversions - monitor governance and terms.
- Legal/IP contingencies: Strand claim (accrued $0.4M estimate) and St George Street Capital IP claim (not accrued; outcome uncertain).
- Fair‑value volatility: convertible notes and liability‑classified warrants (Level 3 inputs) drive swings in reported other income/(expense).
- Dilution & dilution risk: large share issuances (ATM, conversions, prepaid share settlements) materially increased outstanding shares year‑to‑date.

Bottom line - straight takeaways
- The company is actively funding development (R&D ramp, Sarborg platform) and has replenished cash this quarter via ATM sales, but it remains loss‑making with a high burn rate and material going‑concern risk.
- Restatement and significant related‑party transactions increase complexity and investor risk; fair‑value accounting for convertible instruments creates earnings volatility.
- Short‑term positive: cash balance improved to $2,130 (in thousands) and equity turned positive $3,080 (in thousands) at Mar 31, 2025. Long‑term outcome depends on execution, asset value realization (licenses or exits), and the company's ability to raise additional capital on acceptable terms.